[go: up one dir, main page]

SI1420827T1 - 5-CNAC kot sredstvo za oralno dajanje fragmentov paratiroidnega hormona - Google Patents

5-CNAC kot sredstvo za oralno dajanje fragmentov paratiroidnega hormona

Info

Publication number
SI1420827T1
SI1420827T1 SI200230866T SI200230866T SI1420827T1 SI 1420827 T1 SI1420827 T1 SI 1420827T1 SI 200230866 T SI200230866 T SI 200230866T SI 200230866 T SI200230866 T SI 200230866T SI 1420827 T1 SI1420827 T1 SI 1420827T1
Authority
SI
Slovenia
Prior art keywords
parathyroid hormone
oral delivery
cnac
delivery agent
hormone fragments
Prior art date
Application number
SI200230866T
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1420827T1 publication Critical patent/SI1420827T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200230866T 2001-08-17 2002-08-16 5-CNAC kot sredstvo za oralno dajanje fragmentov paratiroidnega hormona SI1420827T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments
EP02794796A EP1420827B8 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number Publication Date
SI1420827T1 true SI1420827T1 (sl) 2010-01-29

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230866T SI1420827T1 (sl) 2001-08-17 2002-08-16 5-CNAC kot sredstvo za oralno dajanje fragmentov paratiroidnega hormona

Country Status (26)

Country Link
US (4) US20040242478A1 (sl)
EP (1) EP1420827B8 (sl)
JP (2) JP4959917B2 (sl)
KR (1) KR20040030120A (sl)
CN (1) CN1279981C (sl)
AT (1) ATE443527T1 (sl)
AU (1) AU2002333443C1 (sl)
BR (1) BRPI0211932B1 (sl)
CA (1) CA2453646C (sl)
CO (1) CO5560586A2 (sl)
CY (1) CY1109661T1 (sl)
DE (1) DE60233803D1 (sl)
DK (1) DK1420827T3 (sl)
EC (1) ECSP044961A (sl)
ES (1) ES2333587T3 (sl)
HU (1) HUP0401441A3 (sl)
IL (2) IL159714A0 (sl)
MX (1) MXPA04001418A (sl)
NO (1) NO328069B1 (sl)
NZ (1) NZ531018A (sl)
PL (1) PL210258B1 (sl)
PT (1) PT1420827E (sl)
RU (1) RU2322256C2 (sl)
SI (1) SI1420827T1 (sl)
WO (1) WO2003015822A1 (sl)
ZA (1) ZA200400242B (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529439A (en) * 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
PT1420827E (pt) * 2001-08-17 2009-12-15 Novartis Ag 5-cnac como agente de administração oral de fragmentos da hormona paratiróide
WO2003086408A1 (en) * 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
BRPI0412265A (pt) 2003-07-23 2006-09-05 Novartis Ag uso de calcitonina em osteoartrite
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP2008543855A (ja) * 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
JP2009508875A (ja) 2005-09-19 2009-03-05 エミスフェアー・テクノロジーズ・インク Ｎ−（５−クロロサリチロイル）−８−アミノカプリル酸二ナトリウム塩の結晶形
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
EP2059260B1 (en) * 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
AU2008223108B2 (en) 2007-03-02 2013-10-10 Novartis Ag Oral administration of a calcitonin
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN113694190B (zh) * 2015-02-09 2024-05-07 安特拉贝欧有限公司 骨质疏松症的治疗
AU2017311698B2 (en) 2016-08-17 2024-09-05 Entera Bio Ltd. Formulations for oral administration of active agents
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
NZ246456A (en) * 1991-12-17 1997-03-24 Procter & Gamble Pharma Use of bone active phosphonate and a parathyroid hormone to prepare medicaments for a thirty day treatment regimen for osteoporosis
NZ257212A (en) * 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
JP4122061B2 (ja) * 1996-08-02 2008-07-23 ナショナル リサーチ カウンシル オブ カナダ 骨粗鬆症の治寮のための副甲状腺ホルモン類似体
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK0993831T3 (da) * 1997-02-07 2008-03-25 Emisphere Tech Inc Forbindelser og præparater til tilförsel af aktive stoffer
WO2000031137A1 (en) * 1998-11-25 2000-06-02 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
ES2386263T3 (es) * 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
NZ529439A (en) * 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
PT1420827E (pt) * 2001-08-17 2009-12-15 Novartis Ag 5-cnac como agente de administração oral de fragmentos da hormona paratiróide
AU2004255458B2 (en) * 2003-07-11 2007-09-13 Emisphere Technologies, Inc. Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
PT1420827E (pt) 2009-12-15
US20090264367A1 (en) 2009-10-22
US9272040B2 (en) 2016-03-01
RU2004107899A (ru) 2005-05-10
JP2009242410A (ja) 2009-10-22
PL210258B1 (pl) 2011-12-30
DE60233803D1 (de) 2009-11-05
BR0211932A (pt) 2004-10-26
CA2453646A1 (en) 2003-02-27
US20120088725A1 (en) 2012-04-12
EP1420827B8 (en) 2009-12-23
NO328069B1 (no) 2009-11-23
JP2005501852A (ja) 2005-01-20
WO2003015822A1 (en) 2003-02-27
BRPI0211932B1 (pt) 2016-12-06
EP1420827B1 (en) 2009-09-23
RU2322256C2 (ru) 2008-04-20
HUP0401441A2 (hu) 2004-12-28
JP4959917B2 (ja) 2012-06-27
PL365388A1 (en) 2005-01-10
EP1420827A1 (en) 2004-05-26
CY1109661T1 (el) 2014-08-13
US20040242478A1 (en) 2004-12-02
DK1420827T3 (da) 2009-12-21
ATE443527T1 (de) 2009-10-15
CO5560586A2 (es) 2005-09-30
CN1543357A (zh) 2004-11-03
AU2002333443C1 (en) 2009-10-08
ES2333587T3 (es) 2010-02-24
AU2002333443B2 (en) 2006-06-29
MXPA04001418A (es) 2004-05-27
NZ531018A (en) 2006-03-31
CA2453646C (en) 2008-09-30
US20060217313A1 (en) 2006-09-28
HUP0401441A3 (en) 2012-09-28
CN1279981C (zh) 2006-10-18
KR20040030120A (ko) 2004-04-08
IL159714A0 (en) 2004-06-20
IL159714A (en) 2010-12-30
NO20040598L (no) 2004-02-10
ZA200400242B (en) 2004-11-18
ECSP044961A (es) 2004-03-23

Similar Documents

Publication Publication Date Title
IL159714A0 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
IL159996A0 (en) Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003047504A3 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2002041837A3 (en) Treatment of mucositis
GT199700009AA (es) Terapia combinada para la osteoporosis
FR06C0032I1 (sl)
ZA200308625B (en) Orally administering parathyroid hormone and calcitonin.
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL370361A1 (en) Alkyl urea retinoid agonists i
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
MXPA05000978A (es) Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
WO2002074315A8 (de) Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
PL370459A1 (en) Substituted urea retinoid agonists ii
AU2003286617A8 (en) Calcitonin drug-oligomer conjugates, and uses thereof
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
IL166678A0 (en) 17?-estradiol/levonorgestrel transderm patch for hormone replacement therapy
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
EP1408043A8 (en) 2''oxo-voruscharin and analogues thereof
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture